Zynerba presents two posters on Zygel at the Society of Biological Psychiatry 2021 Virtual Meeting
The posters highlight the company s progress with Zygel, a CBD-based gel for use as a therapy for Fragile X Syndrome Both posters will be made available on the Zynerba corporate website at http://zynerba.com/publications/
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting.
Both posters will be made available on the Zynerba corporate website.
The first poster titled, “Cannabidiol in Fragile X Syndrome (FXS): Proposed Mechanism of Action (MOA) Translates Into Meaningful Clinical Benefits [CONNECT-FX (ZYN2-CL-016)]” describes responder thresholds representing individual patient-level changes that the company believes are indicative of meaningful treatment be
NA Proactive news snapshot: Lexaria Bioscience Corp, New Pacific Metals Corp, HempFusion Wellness Inc, Gevo Inc, Information Services Corporation, Century Global Commodities Corporation, CleanSpark Inc, Alpine 4 Holdings Inc, Karora Resources Inc UPDATE
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
NA Proactive news snapshot: Lexaria Bioscience Corp, New Pacific Metals Corp, HempFusion Wellness Inc, Gevo Inc, Information Services Corporation, Century Global Commodities Corporation, CleanSpark Inc, Alpine 4 Holdings Inc, Karora Resources Inc UPDATE
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.